COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
BioNxt reports successful preclinical study results for sublingual oral dissolvable film (ODF) cladribine formulation in treating Multiple Sclerosis (MS), achieving higher systemic drug delivery than oral tablets -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
BioNxt Solutions reports successful comparative pharmacokinetics study in pigs for sublingual cladribine ODF formulation, showing superior bioavailability and potential benefits for Multiple Sclerosis therapy. Internal analysis ongoing -
-
-
COMMUNIQUÉ DE PRESSE
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
BioNxt Solutions Inc. announces breakthrough in drug delivery for dysphagia, securing first national-level patent for thin-film platform, targeting autoimmune markets with bioequivalent cladribine treatment
